{"pmid":32361688,"pmcid":"PMC7177122","title":"Can glycopyrrolate come to the airway rescue in Covid-19 patients?","text":["Can glycopyrrolate come to the airway rescue in Covid-19 patients?","J Clin Anesth","Garg, Heena","32361688"],"journal":"J Clin Anesth","authors":["Garg, Heena"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361688","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jclinane.2020.109843","e_drugs":["Glycopyrrolate"],"topics":["Prevention"],"weight":1,"_version_":1666138495500943360,"score":9.490897,"similar":[{"pmid":32442347,"title":"The role of ECMO in COVID-19: Can it provide rescue therapy in those who are critically ill?","text":["The role of ECMO in COVID-19: Can it provide rescue therapy in those who are critically ill?","Arising from the city of Wuhan, Hubei province in China, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 has been rapidly spreading since its first presentation in late 2019. The World Health Organization declared a pandemic on the 11th March 2020, and as of 29th of April 2020 more than 3 million cases have been reported worldwide with over 225 000 confirmed deaths. Where mechanical ventilation may not be enough, extracorporeal membrane oxygenation (ECMO) could play a role as a form of rescue therapy and may provide beneficial results in the hands of skilled clinicians in centers with experience of using ECMO appropriately in selected patients. Our understanding of COVID-19 is ever-changing and the need for intensive care beds is rising, which means that ECMO will surely play a key role in the near future.","J Card Surg","Savarimuthu, Sugeevan","BinSaeid, Jalal","Harky, Amer","32442347"],"abstract":["Arising from the city of Wuhan, Hubei province in China, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 has been rapidly spreading since its first presentation in late 2019. The World Health Organization declared a pandemic on the 11th March 2020, and as of 29th of April 2020 more than 3 million cases have been reported worldwide with over 225 000 confirmed deaths. Where mechanical ventilation may not be enough, extracorporeal membrane oxygenation (ECMO) could play a role as a form of rescue therapy and may provide beneficial results in the hands of skilled clinicians in centers with experience of using ECMO appropriately in selected patients. Our understanding of COVID-19 is ever-changing and the need for intensive care beds is rising, which means that ECMO will surely play a key role in the near future."],"journal":"J Card Surg","authors":["Savarimuthu, Sugeevan","BinSaeid, Jalal","Harky, Amer"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442347","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jocs.14635","keywords":["covid-19","ecmo","critical care","extracorporeal membrane oxygenation"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667535119484715009,"score":42.110504},{"pmid":32417181,"title":"COVID-19: CADD to the rescue.","text":["COVID-19: CADD to the rescue.","The recent outbreak of the deadly COVID-19 disease, being caused by the novel coronavirus (SARS-CoV-2), has put the world on red alert as it keeps spreading and recording more fatalities. Research efforts are being carried out to curtail the disease from spreading as it has been declared as of global health emergency. Hence, there is an exigent need to identify and design drugs that are capable of curing the infection and hinder its continual spread across the globe. Herein, a computer-aided drug design tool known as the virtual screening method was used to screen a database of 44 million compounds to find compounds that have the potential to inhibit the surface glycoprotein responsible for virus entry and binding. The consensus scoring approach selected three compounds with promising physicochemical properties and favorable molecular interactions with the target protein. These selected compounds can undergo lead optimization to be further developed as drugs that can be used in treating the COVID-19 disease.","Virus Res","Onawole, Abdulmujeeb T","Sulaiman, Kazeem O","Kolapo, Temitope U","Akinde, Fatimo O","Adegoke, Rukayat O","32417181"],"abstract":["The recent outbreak of the deadly COVID-19 disease, being caused by the novel coronavirus (SARS-CoV-2), has put the world on red alert as it keeps spreading and recording more fatalities. Research efforts are being carried out to curtail the disease from spreading as it has been declared as of global health emergency. Hence, there is an exigent need to identify and design drugs that are capable of curing the infection and hinder its continual spread across the globe. Herein, a computer-aided drug design tool known as the virtual screening method was used to screen a database of 44 million compounds to find compounds that have the potential to inhibit the surface glycoprotein responsible for virus entry and binding. The consensus scoring approach selected three compounds with promising physicochemical properties and favorable molecular interactions with the target protein. These selected compounds can undergo lead optimization to be further developed as drugs that can be used in treating the COVID-19 disease."],"journal":"Virus Res","authors":["Onawole, Abdulmujeeb T","Sulaiman, Kazeem O","Kolapo, Temitope U","Akinde, Fatimo O","Adegoke, Rukayat O"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32417181","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.virusres.2020.198022","keywords":["cadd","covid-19","coronavirus","sars-cov-2","virtual screening","zoonotic diseases"],"topics":["Treatment"],"weight":1,"_version_":1667058206774394880,"score":41.82252}]}